# OPTIMISING DRUG THERAPY IN OLDER PERSONS: DESIGN AND IMPLEMENTATION OF A MEDICATION ASSESSMENT TOOL FOR **SECONDARY PREVENTION OF STROKE**

Marise Gauci, Francesca Wirth, Lilian M. Azzopardi, Anthony Serracino-Inglott

**Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta** 

marise.gauci@um.edu.mt


## INTRODUCTION

Several characteristics of ageing make selection of drug therapy a challenging appropriate task. **Optimisation of drug therapy in older persons may be** facilitated by application of medication assessment tools.

# **OBJECTIVES**

To design, psychometrically evaluate and implement a medication assessment tool for secondary prevention of stroke (MAT-CVA) with particular relevance to older persons to assess adherence to clinical practice guidelines.





**Department of Pharmacy** 

**University of Malta** 

**DI-059** 

- Development of MAT-CVA involved selection of key criteria from clinical practice guidelines for secondary prevention of stroke, which were presented as a 'qualifying statement' followed by a 'standard'. An application guide was compiled where justifications for non-adherence were specified.
- Content validity was tested using a two-round Delphi process among an expert group consisting of nine reviewers. The application guide was reviewed based on recommendations by the expert group in both rounds. Inter- and intraobserver reliability testing was conducted with agreement expressed by Cohen's kappa (k) and application time measured to assess feasibility.
- The designed MAT-CVA was applied to 150 patients with a history of stroke/transient ischaemic attack admitted to Rehabilitation Hospital Karin Grech, a geriatric and rehabilitation hospital.

### RESULTS

- The developed MAT-CVA consists of 17 criteria (Figure 1).
- Content validity was demonstrated for all criteria

**MAT-CVA** Medication assessment tool for secondary prevention of ischaemic CVA in patients ≥60 years Patient Qualifying statement (q) Standard (s) assessment Patient name: Patient with is chaemic CVA/TIA... Date: ID number:

**Figure 1: The developed MAT-CVA** 

(consensus threshold 75%).

- Reliability was confirmed with κ-values of 0.80 for both intra-observer agreements. and Mean interapplication times were 5.55 (SD 1.96) and 6.56 minutes (SD 1.74) with significant correlation for both interobserver (r=0.6, p=0.001) and intra-observer tests (r=0.8, p=<0.001 and r=0.4, p=0.032).
- 60.7% of the study population were female and mean age was 79.5 years (SD 8.2). 1363 criteria (53.5%) out of a total of 2550 were applicable. Adherence to applicable criteria was 55% and justified non-22.3%. Non-adherence adherence was was predominantly evident for prescription of anticoagulation in atrial fibrillation (36.4%), thiazide diuretics +/- ACE inhibitors for hypertension (26.8%) and dipyridamole at recommended dose (24.0%). Monitoring of HbA1c was deficient in 57.1% of

		id number.				
	Antithrombotic therapy		NA	Y	N/Nj	ID q/s
1		is prescribed aspirin 75mg daily or clopidogrel 75mg daily				
2	w ho is prescribed aspirin	is prescribed dipyridamole mr 200mg twice daily or equivalent				
3	w ho is not prescribed aspirin or clopidogrel due to contraindication/intolerance	is prescribed dipyridamole mr 200mg twice daily or equivalent				
4	w ho has atrial fibrillation	is prescribed warfarin (INR 2.0-3.0) or other oral anticoagulant instead of antiplatelet agents				
	Lipid lowering therapy					
5		is prescribed a statin				
6	w ho is prescribed a statin	is prescribed simvastatin 20-40mg daily or alternative moderate-intensity statin				
7	w ho is prescribed a moderate-intensity statin and LDL >2mmol/L	is prescribed a high-intensity statin				
8	w ho is prescribed a statin and eGFR <30 ml/min/1.73 $m^2$	is prescribed fluvastatin or atorvastatin				
9	w ho is managed w ith a statin	has monitoring of liver function within 3 months of initiation or up-titration				
10	w ho is managed w ith a statin	has monitoring of liver function 12 months after initiation or up-titration				
	Antihypertensive therapy					
11		has systolic blood pressure of <140mmHg and diastolic blood pressure <90mmHg				
12	w ho requires antihypertensive therapy	is prescribed a thiazide diuretic alone or in combination with an ACE inhibitor				
13	w ho is managed w ith a thiazide diuretic	has monitoring of serum electrolytes				
14	w ho is managed w ith an ACE inhibitor	has monitoring of renal function and serum potassium				
	Glycaemic therapy					
15		has HbA <sub>1c</sub> of <7.5%				
16	w ho requires glycaemic therapy	has HbA <sub>1c</sub> betw een 7.0-7.5%				
17	w ho requires glycaemic therapy	has pre-meal blood glucose levels betw een 6.0-8.0mmol/L				

#### patients.

CVA cerebrovascular accident, TIA transient ischaemic attack NA not applicable, Y yes, N no, Nj justified no, IDq insufficient data for qualifying statement, IDs insufficient data for standard References: NICE 2010, RCP 2012, AHA/ASA 2014

# **CONCLUSION**

Content validity, reliability and feasibility of MAT-CVA have been demonstrated. Application of MAT-CVA criteria indicated good overall adherence and highlighted specific gaps in clinical performance which may be targeted to enhance optimisation of drug therapy.

#### **Acknowledgements**

The authors would like to thank Professor Liberato Camilleri, Head of the Department of Statistics and Operations Research in the Faculty of Science at the University of Malta, for his assistance with the statistical analysis. The authors would also like to thank the consultant geriatricians, consultant neurologists and clinical pharmacists who participated in the validity, reliability and feasibility testing.